Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases

• Published in: Journal of controlled release 2022-08, Vol.348, p.264-286
• Main Authors: Rahiman, Niloufar, Markina, Yuliya V., Kesharwani, Prashant, Johnston, Thomas P., Sahebkar, Amirhossein
• Format: Article
• Language: English
• Subjects: Autoimmunity; Curcumin; Inflammatory bowel disease (IBD); Multiple sclerosis (MS); Nanocarriers; Psoriasis; Rheumatoid arthritis (RA); Type I diabetes (T1D)
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2022.05.046

Autoimmune diseases usually arise as a result of an aberrant immune system attack on normal tissues of the body, which leads to a cascade of inflammatory reactions. The immune system employs different types of protective and anti-inflammatory cells for the regulation of this process. Curcumin is a known natural anti-inflammatory agent that inhibits pathological autoimmune processes by regulating inflammatory cytokines and their associated signaling pathways in immune cells. Due to the unstable nature of curcumin and its susceptibility to either degradation, or metabolism into other chemical entities (i.e., metabolites), encapsulation of this agent into various nanocarriers would appear to be an appropriate strategy for attaining greater beneficial effects from curcumin as it pertains to immunomodulation. Many studies have focused on the design and development of curcumin nanodelivery systems (micelles, dendrimers, and diverse nanocarriers) and are summarized in this review in order to obtain greater insight into novel drug delivery systems for curcumin and their suitability for the management of autoimmune diseases. [Display omitted]